---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-001831"
form_type: "8-K"
ticker: "CLSDQ"
cik: "0001539029"
company_name: "Clearside Biomedical, Inc."
filed_at: "2023-02-06T23:59:59+00:00"
generated_at: "2026-06-20T00:03:24.685847+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Clearside Biomedical CMO/CVO Thomas Ciulla resigns effective Feb 17; will serve as advisor

## Summary
- Thomas Ciulla resigns as Chief Medical Officer and Chief Development Officer of Clearside Biomedical.
- Resignation effective February 17, 2023; he will continue as Chairman of Scientific Advisory Board.
- Ciulla will also serve as Chief Medical Advisor – Retina under a proposed consulting agreement.
- No successor named; Ciulla’s advisory role aims to maintain continuity in clinical development.

## SEC filing metadata
- accession: 0000950170-23-001831
- form_type: 8-K
- ticker: CLSDQ
- cik: 0001539029
- company_name: Clearside Biomedical, Inc.
- filed_at: 2023-02-06T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1539029/000095017023001831/0000950170-23-001831-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1539029/000095017023001831/clsd-20230202.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-001831
- JSON: https://secwatch.observer/filing/0000950170-23-001831.json
- Plain text: https://secwatch.observer/filing/0000950170-23-001831.txt

## Key facts
- Executive change
  Thomas Ciulla resigned as Chief Medical Officer and Chief Development Officer at Clearside Biomedical, Inc..
  - Action: resigned
  - Role: Chief Medical Officer and Chief Development Officer
  source text: On February 2, 2023, Thomas Ciulla provided Clearside Biomedical, Inc. (the “ Company ”) notice of his resignation from his position as Chief Medical Officer and Chief Development Officer of the Company, with such resignation to be effective on February 17. 2023
  evidence_url: https://www.sec.gov/Archives/edgar/data/1539029/000095017023001831/0000950170-23-001831-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.